Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors This is an ASCO Meeting Abstract from the 2008 ASCO Annual Meeting. This ...
A metanalysis of the efficacy and safety of pegylated liposomal doxorubicin. Methods: 27 adult ECOG 0-1 patients with RECIST measureable histologically confirmed nonhematologic malignancies that have ...
SANTA MONICA, CA / ACCESSWIRE / January 22, 2018 / Parallax Health Sciences, Inc. ("Parallax" or the "Company") (OTC PINK: PRLX), the owner of patented human diagnostics technologies announced today ...
Company Receives Over $10 million of Telehealth and Medical Supply Contracts from Coast to Coast NEW YORK, NY, April 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Parallax Health Sciences, Inc.
Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...
A high-level overview of Parallax Health Sciences, Inc. (PRLX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results